ESMO 2024: Optimising the personalisation of prostate cancer treatment
Dr Davide Bedognetti presents at ecancer's Milan Summit on Precision Medicine 2018 about immune responsiveness in cancer.
He discusses the genetic determinants behind this, touching upon the Immunologic Constant of Rejection (ICR) pathways and genes involved.
The webcast has been supported by an unrestricted educational grant from Roche Foundation Medicine
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Multiple myeloma In Rwanda: The need for further research
GIST tumours and soft tissue sarcomas
Multiple myeloma in a resource constrained setting
Remote genetic testing has the potential to increase the uptake of testing in large integrated healthcare systems
Relapsed refractory multiple myeloma
The current status of multiple myeloma diagnosis and treatment
Choosing Wisely in pathology
Choosing Wisely in radiology Tanzania